Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical AT193 in Nail Psoriasis
NCT05072886Phase 1Unknown
- Sponsor
- Azora Therapeutics
- Start
- Apr 2022
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in nail psoriasis comparing AT193 with Placebo (2 arms). Primary endpoint: Incidence of treatment-emergent adverse events at 16 weeks. Status: unknown.
02
Drugs
AT-193
03
Conditions
nail psoriasis
Beyond the preview
Go deeper on NCT05072886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05072886.